Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

Affiliations

• ¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
• ² Department of Medicine, University of Washington, Seattle, Washington.
• ³ Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
• ⁴ SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
• ⁵ Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
• ⁶ Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Madison.
• ⁷ SWOG Operations, San Antonio, Texas.
• ⁸ Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
• ⁹ Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
• ¹⁰ Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
• ¹¹ Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina.
• ¹² Department of Medicine, Queen's University, Kingston, Ontario, Canada.
• ¹³ Jewish General Hospital, Montreal, Quebec, Canada.
• ¹⁴ Moffitt Cancer Center, Tampa, Florida.
• ¹⁵ Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
• ¹⁶ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
• ¹⁷ Adult Leukemia Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
• ¹⁸ Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.